И. С. Владимирова
S. M. Kirov Military Medical Academy · 16 works · 15 citations · h-index 3
Top works
- Possibilities of enhancement of the efficiency of complex psoriasis treatment
- Недостаточность магния – достоверный фактор риска коморбидных состояний: результаты крупномасштабного скрининга магниевого статуса в регионах России
- Efficacy of Therapy with the Interleukin-23 Inhibitor а Guselkumab and Quality of Life Indicators in Patients with Psoriasis
- Psoriasis and cardiovascular comorbidity (literature review)
- Efficacy of treatment of patients with psoriasis with anxiety and depression with interleukin‑23 inhibitor guselkumab
- The effectiveness of the treatment of psoriasis with IL-17 inhibitor in a patient with concomitant obesity: a clinical case
- Psoriatic erythroderma and the efficacy of the IL-23 inhibitor guselkumab in clinical practice
- Psoriasis and Comorbidity of Mental Pathology: Parallels and Intersections
- Российский междисциплинарный консенсус по определению «Сложный для ведения» и «Трудный для лечения» псориатический артрит / псориаз и ведению этих пациентов. Положения дерматовенерологов
- Russian interdisciplinary consensus on the definition of “Complex to manage” and “Difficult to treat” psoriatic arthritis/psoriasis and the management of these patients. Positions of dermatovenerologists
- Efficacy of interleukin 17 inhibitor therapy in overweight and obese psoriasis patients (preliminary data)
- Russian interdisciplinary consensus on the definitions of “difficult-to-manage” and “difficult-to-treat” psoriatic arthritis/psoriasis and the management of these patients
- Psoriasis with facial skin lesions that arose against background of withdrawal of ixekizumab (clinical case)
- Влияние недифференцированной дисплазии соединительной ткани на исходы беременности и родов. Комплексное обследование беременных с дисплазией соединительной ткани с использованием методов интеллектуального анализа данных
- Psoriasis, metabolic syndrome and COVID-19: a case report
- Psoriasis, comorbid obesity, and the efficacy of the IL‑23 inhibitor guselkumab based on clinical cases